Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference Presentations highlight key preclinical data that support investigational new drug...
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers Global Phase 1 clinical trial will evaluate the safety and tolerability...
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on...
Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology...
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases...
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage...
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate VANCOUVER, British...
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME...
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers VANCOUVER, British...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0.4 | 3.44827586207 | 11.6 | 12.4 | 11.6 | 496 | 12.26693548 | DE |
12 | 2.95 | 32.5966850829 | 9.05 | 12.4 | 9.05 | 471 | 10.86157624 | DE |
26 | 3.75 | 45.4545454545 | 8.25 | 12.4 | 7.75 | 495 | 9.22687901 | DE |
52 | 5.4 | 81.8181818182 | 6.6 | 12.4 | 6.438 | 503 | 9.26831683 | DE |
156 | 5.236 | 77.4098166765 | 6.764 | 12.4 | 5.876 | 544 | 8.82768567 | DE |
260 | 5.236 | 77.4098166765 | 6.764 | 12.4 | 5.876 | 544 | 8.82768567 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.